CCDC177

Summary

CCDC177 (coiled-coil domain containing 177, HGNC:23243) is a protein-coding gene on chromosome 14q24.1, encoding Coiled-coil domain-containing protein 177 (Q9NQR7).

At a glance

• MANE Select transcript: NM_001271507

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:23243
Approved symbol	CCDC177
Name	coiled-coil domain containing 177
Location	14q24.1
Locus type	gene with protein product
Status	Approved
Aliases	PLPL
Ensembl gene	ENSG00000267909
Ensembl biotype	protein_coding
Entrez	56936

Gene structure

Transcript identifiers

Ensembl transcripts: 1 — 1 protein_coding

ENST00000599174

RefSeq mRNA: 1 — MANE Select: NM_001271507 NM_001271507

CCDS: CCDS59245

Canonical transcript exons

ENST00000599174 — 2 exons

Exon	Start	End
ENSE00003040691	69569799	69573650
ENSE00003728799	69574542	69574871

Expression profiles

Bgee: expression breadth broad, 58 present calls, max score 88.61.

FANTOM5 (CAGE): breadth tissue_specific, TPM avg 0.6327 / max 37.1508, expressed in 174 samples.

FANTOM5 promoters (1 alternative TSS)

Promoter ID	TPM avg	Samples expressed
143887	0.6327	174

Top tissues by expression

270 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
secondary oocyte	CL:0000655	88.61	gold quality
oocyte	CL:0000023	83.02	gold quality
ganglionic eminence	UBERON:0004023	79.97	gold quality
ventricular zone	UBERON:0003053	78.77	gold quality
cortical plate	UBERON:0005343	76.45	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	73.45	gold quality
cerebellum	UBERON:0002037	70.63	gold quality
cerebellar cortex	UBERON:0002129	69.71	gold quality
cerebellar hemisphere	UBERON:0002245	69.56	gold quality
right hemisphere of cerebellum	UBERON:0014890	68.90	gold quality
prefrontal cortex	UBERON:0000451	68.46	gold quality
cerebellar vermis	UBERON:0004720	68.22	silver quality
postcentral gyrus	UBERON:0002581	68.06	gold quality
embryo	UBERON:0000922	67.75	gold quality
tibialis anterior	UBERON:0001385	67.32	silver quality
parietal lobe	UBERON:0001872	66.44	gold quality
frontal cortex	UBERON:0001870	66.20	gold quality
superior frontal gyrus	UBERON:0002661	65.71	gold quality
neocortex	UBERON:0001950	65.41	gold quality
entorhinal cortex	UBERON:0002728	65.20	silver quality
primary visual cortex	UBERON:0002436	65.14	gold quality
endothelial cell	CL:0000115	64.67	gold quality
cerebral cortex	UBERON:0000956	64.07	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	64.02	gold quality
middle temporal gyrus	UBERON:0002771	63.56	silver quality
right frontal lobe	UBERON:0002810	63.47	gold quality
Brodmann (1909) area 9	UBERON:0013540	63.15	gold quality
occipital lobe	UBERON:0002021	63.12	gold quality
Brodmann (1909) area 23	UBERON:0013554	62.11	silver quality
anterior cingulate cortex	UBERON:0009835	60.57	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	1.97

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

100 targeting CCDC177, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-200B-3P	100.00	73.31	2693
HSA-MIR-200C-3P	100.00	73.35	2685
HSA-MIR-429	100.00	73.44	2698
HSA-MIR-4510	100.00	66.60	2050
HSA-MIR-6127	100.00	66.76	2188
HSA-MIR-6129	100.00	66.46	2080
HSA-MIR-6130	100.00	66.69	2012
HSA-MIR-6133	100.00	66.48	2064
HSA-MIR-3667-3P	99.99	67.17	1636
HSA-MIR-4482-3P	99.98	72.50	3147
HSA-MIR-12136	99.98	72.81	5713
HSA-MIR-548AN	99.97	70.91	2817
HSA-MIR-3065-5P	99.97	71.56	3281
HSA-MIR-9-3P	99.96	70.88	2068
HSA-MIR-6721-5P	99.93	68.92	2981
HSA-MIR-515-5P	99.92	69.82	2343
HSA-MIR-519E-5P	99.92	69.62	2358
HSA-MIR-124-3P	99.89	73.74	3043
HSA-MIR-506-3P	99.89	73.55	3057
HSA-MIR-605-3P	99.88	69.22	1833
HSA-MIR-4492	99.87	68.25	3611
HSA-MIR-548AZ-5P	99.83	69.94	3230
HSA-MIR-548T-5P	99.83	69.91	3220
HSA-MIR-1323	99.83	69.89	2471
HSA-MIR-8080	99.82	67.52	1342
HSA-MIR-4495	99.82	72.08	3080
HSA-MIR-6739-5P	99.80	67.87	2806
HSA-MIR-6745	99.74	65.33	1321
HSA-MIR-6733-5P	99.74	67.94	2759
HSA-MIR-8084	99.73	69.57	1760

Cross-species orthologs

2 orthologs

Organism	Symbol	Gene ID
mus_musculus	Ccdc177	ENSMUSG00000062961
rattus_norvegicus	Ccdc177	ENSRNOG00000033973

Protein

Protein identifiers

Coiled-coil domain-containing protein 177 — Q9NQR7 (reviewed: Q9NQR7)

Alternative names: Myelin proteolipid protein-like protein

All UniProt accessions (1): Q9NQR7

RefSeq proteins (1): NP_001258436* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR029090	DUF4659	Family

Pfam: PF15558

UniProt features (21 total): compositionally biased region 12, region of interest 6, chain 1, modified residue 1, coiled-coil region 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9NQR7-F1	75.05	0.37

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (1): 311

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 48 (showing top): AHRARNT_01, MYOGENIN_Q6, PAX4_01, LFA1_Q6, GCANCTGNY_MYOD_Q6, GGAMTNNNNNTCCY_UNKNOWN, CAGCTG_AP4_Q5, GTGCCTT_MIR506, chr14q24, TGGNNNNNNKCCAR_UNKNOWN, TGCCTTA_MIR124A, DR3_Q4, OSF2_Q6, AP2_Q6, CAGTGTT_MIR141_MIR200A

GO Biological Process (0):

GO Molecular Function (0):

GO Cellular Component (0):

Protein interactions and networks

STRING

656 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
CCDC177	LENG1	Q96BZ8	563
CCDC177	MYO15B	Q96JP2	537
CCDC177	HRCT1	Q6UXD1	531
CCDC177	TPGS1	Q6ZTW0	493
CCDC177	OOSP1	A8MZH6	470
CCDC177	A0A087WYV9	A0A087WYV9	447
CCDC177	A0A0G2JMU2	A0A0G2JMU2	447
CCDC177	POTEB3	A0JP26	446
CCDC177	FOXN4	Q96NZ1	435
CCDC177	SLC35E2A	P0CK97	413
CCDC177	CYYR1	Q96J86	408
CCDC177	CYFIP2	Q96F07	403
CCDC177	ESX1	Q8N693	398
CCDC177	SPRED3	Q2MJR0	381
CCDC177	C1orf210	Q8IVY1	378

IntAct

3 interactions, top by confidence:

A	B	Type	Score
ORF14	PARP1	psi-mi:“MI:0914”(association)	0.350
	RPS10-NUDT3	psi-mi:“MI:0914”(association)	0.350

BioGRID (1): CCDC177 (Positive Genetic)

ESM2 similar proteins: A0AUP1, A5D8V7, B0BM24, D3ZND0, D6REC4, O60826, P86182, Q15051, Q1RM03, Q1RM35, Q1RMI8, Q2YD98, Q3TVW5, Q494V2, Q499E4, Q4R8V8, Q571B6, Q5BK43, Q5R694, Q5RE49, Q5REX6, Q5SPX1, Q5XIA0, Q62036, Q6NVC9, Q6P5U8, Q7T0Y4, Q7Z4T9, Q8BP00, Q8C2K1, Q8C9J3, Q8CB59, Q8IYY4, Q8N8D1, Q8NCU4, Q8TF30, Q8VDI1, Q95JM8, Q95KD7, Q95LR0

Diamond homologs: Q3UHB8, Q5R694, Q9NQR7

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

0 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	0
Likely benign	0
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

97 predictions. Top by Δscore:

Variant	Effect	Δscore
14:69574538:TCA:T	donor_loss	1.0000
14:69574539:CA:C	donor_loss	1.0000
14:69574540:ACC:A	donor_gain	1.0000
14:69574541:CCC:C	donor_gain	1.0000
14:69574540:A:AC	donor_gain	0.9900
14:69574540:AC:A	donor_gain	0.9900
14:69574541:C:CC	donor_gain	0.9900
14:69574541:CC:C	donor_gain	0.9900
14:69574541:CCCCG:C	donor_gain	0.9900
14:69574548:T:TA	donor_gain	0.9900
14:69573649:CT:C	acceptor_gain	0.9800
14:69573659:C:CT	acceptor_gain	0.9800
14:69574536:ACT:A	donor_loss	0.9800
14:69574540:ACCC:A	donor_gain	0.9800
14:69574541:CCCC:C	donor_gain	0.9800
14:69573648:TCT:T	acceptor_gain	0.9700
14:69573649:CTC:C	acceptor_gain	0.9700
14:69573650:TCT:T	acceptor_gain	0.9700
14:69573651:C:CC	acceptor_gain	0.9700
14:69573651:C:G	acceptor_gain	0.9600
14:69574536:A:AC	donor_gain	0.9600
14:69574537:C:CC	donor_gain	0.9600
14:69573661:C:CT	acceptor_gain	0.9500
14:69573650:TC:T	acceptor_loss	0.9400
14:69573651:C:CA	acceptor_loss	0.9400
14:69573652:T:A	acceptor_loss	0.9400
14:69573662:A:T	acceptor_gain	0.9400
14:69573647:ATCT:A	acceptor_gain	0.9200
14:69574537:CTCA:C	donor_gain	0.8800
14:69573646:AATCT:A	acceptor_gain	0.8700

AlphaMissense

4437 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
14:69573294:A:G	L110P	1.000
14:69573344:G:C	S93R	1.000
14:69573344:G:T	S93R	1.000
14:69573346:T:G	S93R	1.000
14:69573351:A:G	L91P	1.000
14:69572601:A:C	I341S	0.999
14:69572601:A:T	I341N	0.999
14:69573169:G:T	R152S	0.999
14:69573179:G:C	C148W	0.999
14:69573189:A:G	L145P	0.999
14:69573234:G:T	A130D	0.999
14:69573294:A:T	L110Q	0.999
14:69573303:G:T	P107Q	0.999
14:69573304:G:A	P107S	0.999
14:69573309:A:T	V105D	0.999
14:69573323:G:C	C100W	0.999
14:69573324:C:T	C100Y	0.999
14:69573325:A:G	C100R	0.999
14:69573328:C:G	A99P	0.999
14:69573333:A:G	L97P	0.999
14:69573333:A:T	L97Q	0.999
14:69573351:A:T	L91Q	0.999
14:69573358:A:C	Y89D	0.999
14:69573358:A:G	Y89H	0.999
14:69573387:A:G	F79S	0.999
14:69573389:G:C	N78K	0.999
14:69573389:G:T	N78K	0.999
14:69572601:A:G	I341T	0.998
14:69573168:C:G	R152P	0.998
14:69573181:A:G	C148R	0.998

dbSNP variants (sampled 300 via entrez): RS1000167449 (14:69576158 G>A), RS1000253961 (14:69572577 T>C), RS1000285120 (14:69572419 G>A,T), RS1000347949 (14:69570478 A>C,T), RS1000805579 (14:69570183 T>TC), RS1001629778 (14:69575748 C>G,T), RS1002264840 (14:69575226 A>G,T), RS1002287454 (14:69569372 C>G), RS1002313843 (14:69569622 C>G), RS1002437278 (14:69575522 T>A), RS1002843672 (14:69574001 G>A), RS1003849371 (14:69574313 C>T), RS1004160214 (14:69572896 C>T), RS1004252816 (14:69572628 C>A,T), RS1004257143 (14:69570565 C>A)

Disease associations

OMIM: gene `` | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

31 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	decreases expression, increases expression, increases methylation, affects cotreatment	8
bisphenol A	increases expression, decreases expression, affects cotreatment	2
trichostatin A	decreases expression, affects cotreatment	2
mercuric bromide	decreases expression, affects cotreatment	2
entinostat	decreases expression, affects cotreatment	2
Panobinostat	affects cotreatment, decreases expression	2
Phenylmercuric Acetate	affects cotreatment, decreases expression	2
p-Chloromercuribenzoic Acid	affects cotreatment, decreases expression	2
aristolochic acid I	decreases expression	1
bisphenol F	affects cotreatment, increases expression	1
methylmercuric chloride	decreases expression	1
titanium dioxide	decreases expression	1
ferrous chloride	decreases expression	1
S-(1,2-dichlorovinyl)cysteine	affects cotreatment, decreases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, decreases expression	1
dorsomorphin	decreases expression, affects cotreatment	1
bisphenol S	affects cotreatment, increases expression	1
Resveratrol	affects cotreatment, decreases expression	1
Arsenic	affects methylation	1
Benzo(a)pyrene	increases methylation	1
Copper	decreases expression, affects cotreatment	1
Dexamethasone	affects cotreatment, increases expression	1
Indomethacin	affects cotreatment, increases expression	1
Lipopolysaccharides	affects cotreatment, decreases expression	1
Paraoxon	decreases expression	1
Silicon Dioxide	decreases expression	1
Tretinoin	decreases expression	1
1-Methyl-3-isobutylxanthine	affects cotreatment, increases expression	1
Aflatoxin B1	decreases methylation	1
Okadaic Acid	increases expression	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.